PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.25%
G&A growth above 1.5x AGEN's 4.17%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.84%
Operating expenses growth above 1.5x AGEN's 2.54%. Michael Burry would check for inefficiency.
63.84%
Total costs growth above 1.5x AGEN's 2.54%. Michael Burry would check for inefficiency.
217.76%
Interest expense growth above 1.5x AGEN's 2.30%. Michael Burry would check for over-leverage.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
63.84%
Other expenses growth above 1.5x AGEN's 9.40%. Michael Burry would check for concerning trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.24%
Tax expense growth above 1.5x AGEN's 9.40%. Michael Burry would check for concerning trends.
-88.24%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-87.91%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-87.91%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.